The International Swaps and Derivatives Association, Inc. (ISDA) filed a comment letter on September 23 with the Committee on Payment and Settlements Systems (CPSS) and the International Organization of Securities Commissions (IOSCO) in response to their consultative report on over-the-counter (OTC) derivatives data reporting and aggregation requirements.
In the letter, ISDA reiterated the need for a global view of trade repositories (TRs), data reporting and aggregation requirements, and hopes that the CPSS/IOSCO consultative report will assist the fostering of consistency of standards internationally. ISDA has worked with its members and with regulators to establish TRs for credit, interest rate and equity derivatives and industry efforts are continuing to establish TRs for commodities derivatives and foreign exchange contracts.
“An effective, global trade repository infrastructure is a shared aim of the regulatory community and OTC derivatives markets,” said Conrad Voldstad, ISDA’s Chief Executive Officer. “We are concerned that this aim may be undermined by the pursuit of local regulatory mandates that may lead to a fragmented TR system.”
The letter notes that ISDA believes that fragmentation of TRs will introduce operational complexity, undermine risk reduction and impose unnecessary costs. ISDA considers that the role of TRs in systemic oversight makes it essential that they are operationally robust, and that there is no fragmentation of their function.
ISDA’s comment letter to the CPSS and the IOSCO also reiterated the Association’s call for the development of a single “Counterparty Exposure Repository” to provide an aggregated risk view for regulators (of the net mark-to-market exposure for each counterparty portfolio, the corresponding collateral and the firms’ calculation of net exposure after the application of collateral).
The letter expresses strong support for common industry standards to facilitate data aggregation and analysis by regulators and highlights the work the industry is doing with regards to Legal Entity Identifiers (LEIs), Unique Product Identifiers (UPIs) and the development of a product taxonomy or classification for OTC derivatives.